- Home
- APGE vs APLS Comparison
APGE vs APLS Comparison
Compare APGE & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APGE
- APLS
- Stock Information
- Founded
- APGE 2022
- APLS 2009
- Country
- APGE United States
- APLS United States
- Employees
- APGE N/A
- APLS N/A
- Industry
- APGE Biotechnology: Biological Products (No Diagnostic Substances)
- APLS Biotechnology: Pharmaceutical Preparations
- Sector
- APGE Health Care
- APLS Health Care
- Exchange
- APGE Nasdaq
- APLS Nasdaq
- Market Cap
- APGE 2.1B
- APLS 2.2B
- IPO Year
- APGE 2023
- APLS 2017
- Fundamental
- Price
- APGE $44.32
- APLS $17.82
- Analyst Decision
- APGE Strong Buy
- APLS Buy
- Analyst Count
- APGE 4
- APLS 19
- Target Price
- APGE $97.50
- APLS $37.39
- AVG Volume (30 Days)
- APGE 913.3K
- APLS 1.8M
- Earning Date
- APGE 08-11-2025
- APLS 07-31-2025
- Dividend Yield
- APGE N/A
- APLS N/A
- EPS Growth
- APGE N/A
- APLS N/A
- EPS
- APGE N/A
- APLS N/A
- Revenue
- APGE N/A
- APLS $775,839,000.00
- Revenue This Year
- APGE N/A
- APLS $1.01
- Revenue Next Year
- APGE $743.14
- APLS $22.14
- P/E Ratio
- APGE N/A
- APLS N/A
- Revenue Growth
- APGE N/A
- APLS 48.04
- 52 Week Low
- APGE $26.20
- APLS $16.10
- 52 Week High
- APGE $63.50
- APLS $42.47
- Technical
- Relative Strength Index (RSI)
- APGE 61.88
- APLS 46.28
- Support Level
- APGE $42.88
- APLS $17.15
- Resistance Level
- APGE $44.61
- APLS $18.74
- Average True Range (ATR)
- APGE 2.37
- APLS 0.70
- MACD
- APGE 0.12
- APLS -0.06
- Stochastic Oscillator
- APGE 63.45
- APLS 30.89
About APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.